Navigation Links
Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy
Date:12/7/2009

Medroxyprogesterone wins out in comparison study

SUNDAY, Dec. 6 (HealthDay News) -- Hot flashes caused by androgen suppression therapy for prostate cancer are best controlled by the hormonal treatments cyproterone acetate and medroxyprogesterone acetate, according to a new study.

Androgen suppression is considered the gold standard treatment for advanced prostate cancer, but about 80 percent of patients undergoing the treatment experience hot flashes. A number of hormonal and non-hormonal drugs are used to treat the hot flashes, but no direct comparisons of the drugs have been made in clinical trials.

The new study included 311 prostate cancer patients in France undergoing androgen suppression therapy. To treat their hot flashes, they received either the non-hormonal drug venlafaxine (102 men), or one of two hormonal drugs -- cyproterone acetate (101 men) or medroxyprogesterone acetate (108 men). The patients were assessed at weeks four, eight and 12 and asked to complete a questionnaire about the frequency and severity of their hot flashes for the week before each assessment.

The researchers found that all three drugs reduced the occurrence of hot flashes, but the hormonal drugs were much more effective at reducing them over all time periods.

After receiving treatment for four weeks, 219 patients (nearly 71 percent) reported an improvement of at least 50 percent in their hot flash scores, and 70 patients (nearly 23 percent) said they no longer had hot flashes. By the fourth week, hot flash scores were reduced by 47.2 percent for the venlafaxine group, 83.7 percent for the medroxyprogesterone acetate group and 94.5 percent for the cyproterone acetate group.

Among men receiving gonadotrophin-releasing hormone analogue therapy for prostate cancer, cyproterone acetate and medroxyprogesterone acetate are more effective at 12 weeks for treating hot flashes, the researchers concluded. However, "as cyproterone is a recognized treatment in prostate cancer, and its use could interfere with hormone therapy, medroxyprogesterone should be the standard treatment," they wrote.

The study will be published online Dec. 7 in The Lancet Oncology.

More information

The American Urological Association has more about androgen suppression therapy for prostate cancer.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Dec. 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Dr. Rabin Introduces a Bioidentical Hormones Program Adaptable to Individual Body and Hormonal Needs
2. When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research
3. Attorneys Learn of the Association Between Traumatic Brain Injury, Hormonal Deficiencies, Depression, and Heart Attacks
4. Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne
5. Pregnancy-related hormonal changes linked to increased risk of restless legs syndrome
6. Non-Hormonal Therapies Aid Breast Cancer Patients
7. Inheritance of hormonal disorder marked by excessive insulin in daughters
8. Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract
9. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
10. Hormonal dietary supplements might promote prostate cancer progression
11. Hormonal Changes and Depression: What is the Connection?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... , ... “Now Hiring!” is a popular phrase at Home Delivery Incontinent ... sales for over 30 consecutive years and now plans to hire more than 100 ... excitement and growth at HDIS, following the company’s acquisition by Fortune 1000 company Domtar. ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... the launch of their partnership to provide the Pharmacist eCare Plan ... platform in the country with the ability to develop the Pharmacist eCare Plan, ...
(Date:7/25/2017)... Spring Arbor, Mich. (PRWEB) , ... July 25, ... ... director of special education programs at Spring Arbor University recently co-authored and published ... of Self-Determination in Adolescents with Neonatal Brachial Plexus Palsy. Both the article and ...
(Date:7/25/2017)... ... 25, 2017 , ... Facing medical needs with a newborn boy this spring, ... a new benefit for employees that is uncommon in American business: 12 weeks of ... me and other employees as new parents. It keeps our family life more stable. ...
(Date:7/24/2017)... ... 24, 2017 , ... Engineers at the University of Maryland have invented an ... of electrical energy that the body uses. , In ordinary batteries the electrical ... electrons out of the battery is generated by moving positive ions from one end ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 /PRNewswire/ ... University of Alberta in Edmonton, Canada ... partner journal, Schizophrenia 1 , demonstrating that AI ... schizophrenia with 74% accuracy. This retrospective analysis also ... symptoms in schizophrenia patients with significant correlation, based ...
(Date:7/21/2017)... 21, 2017  Endo International plc (NASDAQ: ... review of its manufacturing network, the Company will be ... in Huntsville, Alabama . The closure ... the next 12 to 18 months. The ... volumes of commoditized products and these restructuring actions are ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
Breaking Medicine Technology: